🏅 FDA Orphan Designation
Firdapse
AMIFAMPRIDINE PHOSPHATE
Manufacturer: Catalyst Pharmaceuticals, Inc.
Indicated for:
FDA-Approved Indications (1)
Lambert-Eaton myasthenic syndromeOrphan Designation
Treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults
Indications & Usage
1 INDICATIONS AND USAGE FIRDAPSE ® is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older. FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older. ( 1 )
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.